Impact of Clostridium difficile infection on stroke patients in rehabilitation wards

Intravenous metronidazole for fulminant Clostridioides difficile infection

A large proportions of patients with C difficile infections do not respond to metronidazole.

Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).

In data presented during ACG, investigators found patients with malnutrition and CDI had higher mortality and increased hospitals costs compared to those without malnutrition.

Researchers assessed the effects of adjunctive eravacycline therapy in patients with recurrent, severe, or fulminant Clostridioides difficile infection.

Impact of Clostridium difficile infection on stroke patients in rehabilitation wards

Clostridioides difficile remains a problematic pathogen resulting in significant morbidity and mortality, especially for high-risk groups that include immunocompromised patients. Both the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America (IDSA/SHEA) …

Extended infusion piperacillin/tazobactam was associated with lower odds of 14-day mortality compared to standard infusion piperacillin/tazobactam.

Patients with inflammatory bowel disease (IBD) have a higher incidence of Clostridioides difficile infection (CDI). Previous studies have demonstrated negative clinical outcomes in IBD patients with CDI compared to patients without CDI. The clinical presentation of CDI is indistinguishable from IBD …

Sky-high costs with little wiggle room to negotiate mean fidaxomicin remains underprescribed for recurrent C diff, despite favorable outcomes.

Co-administration of probiotics and antibiotics has been used to prevent or treat primary Clostridioides difficile (pCDI), and the closer the interval between the combination, the more effective it is, but the reason behind this is unknown. In this study, the cell-free culture supernatant (CFCS) of …

Clostridioides difficile is a common cause of community-associated and health care-associated infections. Older adults are disproportionately affected, and long-term care facilities (LTCFs) have borne a substantial proportion of the burden of C difficile infection (CDI). Recurrences of CDI are commo …

The stubborn superbug Clostridium difficile, or C. diff, may have met its match. A esearcher is reporting the first well-controlled study to demonstrate the effectiveness of a new medicine for patients with the debilitating recurrent infection and disease.

Although fecal microbiota, live-jslm (Rebyota; RBX2660) is the first fecal microbiota product approved by the FDA, there are other microbiota-based agents in the pipeline.

Advances in Therapy - The gut microbiota is intrinsically linked to human health; disturbances in microbial homeostasis are implicated in both intestinal and extraintestinal disorders. Probiotics...

Join us for a live, virtual CME/CE-certified 90-minute symposia to gain expert insights on various aspects of CDI care including critical evaluations of clinical practice guidelines and approaches to individualize care by incorporating the patient voice in management decisions. Register Today

Clinical Decisions from The New England Journal of Medicine — Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent Clostridioides difficile Infection

The treatment was well-tolerated, with all serious treatment emergent adverse events considered not related to the treatment.

Rebyota is a fecal microbiota suspension for rectal administration.

There have been only 12 unique studies evaluating this treatment for the primary and secondary prevention of CDI, with only 1 conducted prospectively.

A review of changes to clinical, dietary and screening strategies for patients with GERD.

A new study has shown that zinc plays a key role in a hospital superbug that doctors struggle to treat due to its resistance to antibiotics.

Rebyota-was-approved-by-the-FDA-on-Nov-30-2022-to-prevent-recurrence-of-Clostridioides-difficile-infection-in-people-18-years-of-age-and-older-

Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent Clostridioides difficile Infection

The updated Czech guidelines differ in some aspects from the 2021 guidelines issued by the ESCMID Study Group for Clostridium difficile. The key points of these Czech recommendations may be summarized as follows: • The drug of choice for hospitalized patients is orally administered fidaxomicin or va …

The global Clostridium Diagnostics Market is anticipated to grow at a CAGR of 12.2% from 2022 to 2032, from US$ 2.5 billion to US$ 7.8 billion. The market demonstrated a CAGR of 13.6% from 2015 to 2021. The increasing incidence of clostridium-related illnesses and the expansion of public awarenes...

These treatments were reviewed in a real-world application to evaluate their effectiveness in preventing recurrences.

Clostridioides difficile is a Gram-positive opportunistic pathogen responsible for 250,000 hospital-associated infections, 12,000 hospital-associated deaths, and $1 billion in medical costs in the United States each year. There has been recent interest in using a daptomycin analog, surotomycin, to t …